Full-Time

Senior Clinical Research Director

Deadline 7/27/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$236.3k - $393.8k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

In Person

US residents only.

Category
Biology & Biotech (1)
Required Skills
Ruby
SAP Products
biostatistics
Google Cloud Platform
Requirements
  • At least 4 years previous experience in clinical development in pharmaceutical industry or a CRO or medical experience in clinical development in a Healthcare institution
  • Very good communication skills (verbal and written) for interactions across functional areas and for interactions with key regulatory agencies
  • Excellent problem solving capability
  • Demonstrated capability to challenge decision and status quo with a risk-management approach
  • Quality- focused, able to develop good practices, using a critical data-driven and risk management approach
  • Multiple tasks handling and prioritization
  • Ability to negotiate to ensure operational resources are available for continued clinical conduct
  • Mentoring skills and evaluation of resources performance capability
  • Ability to work within a matrix model
  • International/ intercultural working skills
  • Open-minded to apply new digital solutions
  • Understanding of pharmaceutical product development and life cycle management
  • Very good Scientific and medical/clinical expertise
  • Very good expertise in clinical development and methodology of clinical studies
  • Acquired expertise (by training or experience) of interaction with Health Authorities
  • Medical Doctor (MD) preferred: GP or specialist; training in pediatrics or pediatric neurology is a plus
  • English fluent (spoken and written)
Responsibilities
  • Provide medical expertise in the Study team to conduct the clinical studies from early phases to lifecycle management programs
  • Collaborate with other medical and clinical scientific experts CRDs or DSDs in the project under the leadership of the Global Project Head, with the Global safety Officer, Regulatory Strategist and other key functional representatives to deliver development strategy and prepare/assist with regulatory bodies interaction
  • Develop the study level regulatory documentation (Abbreviated Protocol, Protocol, Amended protocol) for their project, lead other operational development activities pertaining to study start-up (e.g. pressure test, competitive intelligence, patient engagement, cluster feasibility, study risk assessment etc…)
  • Provide appropriate medical input & support for all activities related to clinical studies conduct such as answers to IRBs and HA questions, protocol scientific and medical training, medical review of data within the scope of the Centralized monitoring, clinical and medical information for the study team, medical advisors/Clinical Project Leaders from Clinical Study Units, and investigators
  • Develop the clinical part of Briefing regulatory documents, Common Technical Document for submission to regulatory bodies (FDA, EMA, PMDA etc…) and answers to questions from health authorities.
  • Be the medical reference in the Clinical Study team, ensuring the medical relevance of the clinical data and able to act as mentor for other DMDs/DSDs/CSs, has the capacity to train them on the medical/scientific strategy by indication
  • Leading the clinical development plan strategies:
  • Responsible for the clinical development plans and clinical sections of integrated development plans (IDP)
  • Contribute in the definition of the product value proposition (TVP), Target Product Profile (TPP) and market access strategy (in collaboration with respective functions) and the focus of the research strategy, by providing input on existing clinical needs and approaches to clinical development strategies for research projects
  • Prepares Internal Governance documents and contributes to the medical aspects the TPP, TVP and other GPT documents related to one or several indications of the IDP in support of the GPH
  • Collaborate with other DMDs/DSDs within the project, ensures leadership, builds consensus, coordinates action plans with stakeholders to resolve project-related issues, anticipates potential issues (sharing lessons learned) across the project or study teams
  • Raise study or project-level issues to the project head and propose related corrective action plans
  • Collaborates with external partners, regulators, scientific experts and internal stakeholders
  • Provide operational expertise to project clinical sub team, as needed
  • Evaluates relevant medical literature and status from competitive products
  • Lead, Support and oversee the execution of clinical development and studies activities
  • Collaborate and communicate appropriately with all function stakeholders (e.g. clinical operations, project management, Patient Safety and Pharmacovigilance, regulatory, Finance, Scientific External Engagement, Procurement etc…), responsible for timelines, budgets and contingency/risk management plans to assure successful execution of the clinical trials in compliance with Good Clinical Practice (GCP), applicable laws and regulations as well as applicable standard operating procedures (SOPs)
  • Develop the abbreviated protocol, the final protocol and protocol amendments
  • Develop/review the Core Study Informed Consent Form (CSICF)
  • Develop/review Study committee Charters
  • Collaborate on key medical and clinical questions with the Global feasibility manager to prepare and interpret feasibility and competitive intelligence results
  • Review and provide clinical input across different study documents Vendors RFPs, (e-)CRF,(e-) diary, (e-)CoA, etc
  • Provide medical/clinical input to study-related documents such as study plans e.g. Study risk management plan, Monitoring and centralized monitoring plans
  • Participate in the elaboration of training material and presentations at the investigator meetings/local teams trainings
  • Answer to medical questions raised by HA, EC/IRBs, sites
  • Ensure quality of clinical data through continuous data validation, blinded Data review on summary tables or electronic data visualization during clinical trial conduct (AE dedicated review, and Clinical Case review for safety data and statistical surveillance for efficacy data,…)
  • Ensure trial master file documents readiness and availability, and mandatory trainings linked to the clinical function
  • Lead the study specific committees (IDMC, steering com, adjudication …) with operational support
  • Co-Develop the SAP in collaboration with biostats
  • Responsible for key results preparation
  • Develop/Review the clinical study report
  • Responsibilities related to regulatory and safety documents and meetings:
  • Represent project in interactions with regulatory bodies, leads strategy and write clinical sections of the CTD, briefing docs and supports registration, labelling etc…
  • Develop and/or contribute in the clinical section of the Investigator’s brochure, CTA, IND, DSUR, DRMP, RMP
  • Contribute in the clinical sections of the BLA/CTD, Briefing packages for regulatory meetings, PSP/PIP
  • Ensure clinical data meets all necessary regulatory standards
  • Collaborate with the Patient Safety GSO to detect and document any safety signal
  • Participates in Advisory Committee preparation
  • Scientific Data evaluation and authorship:
  • Participate and author manuscripts and abstracts
  • Establish and maintains appropriate collaborations with knowledge experts or advisory boards
  • Represent medical function on an ad hoc basis to specific tasks such as the evaluation of potential in-licensing candidates for the therapeutic area and serves as the clinical advisor to research teams
Desired Qualifications
  • Training in pediatrics or pediatric neurology is a plus

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sarclisa’s EU on-body injector approval supports at-home multiple myeloma treatment adoption.
  • Owkin’s five-year AI-agent collaboration can speed discovery and clinical development workflows.
  • The Toronto AI hub expansion adds 50 AI roles, strengthening Sanofi’s digital R&D capacity.

What critics are saying

  • Dupixent concentration leaves Sanofi exposed to payer pressure or label disruption.
  • Riliprubart’s phase 3 discontinuation signals fragile late-stage neurology execution.
  • AI initiatives across operations create governance and rollout risks if outputs fail or stall.

What makes Sanofi unique

  • Sanofi is an R&D-driven, AI-powered biopharma company headquartered in Paris.[3][5]
  • Its portfolio spans medicines and vaccines across immunology, oncology, rare diseases, and neurology.[1][3]
  • Sanofi combines global manufacturing with partnerships and licensing to expand reach efficiently.[1][3]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sanofi who can refer or advise you

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Novo Holdings
May 4th, 2026
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential.

Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]

Yahoo Finance
Apr 13th, 2026
Dupixent approved in EU as first targeted medicine for chronic spontaneous urticaria in children aged 2-11

Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years. The approval applies to patients with inadequate response to histamine-1 antihistamines who are naïve to anti-immunoglobulin E therapy. This expands Dupixent's existing EU approval for CSU, which previously covered adults and adolescents aged 12 and older. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. The approval is based on data from the LIBERTY-CUPID clinical trial programme, including efficacy data extrapolated from two Phase 3 adult trials and pharmacokinetic, safety and efficacy data from the CUPIDKids Phase 3 trial in children aged 2 to 11.

The Associated Press
Apr 13th, 2026
EU approves Sanofi and Regeneron's Dupixent as first targeted medicine for young children with chronic urticaria

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged two to 11 years with inadequate response to antihistamines. Developed by Sanofi and Regeneron, this marks the first targeted medicine for young children with the condition in the EU. The approval, based on the LIBERTY-CUPID clinical study programme, expands Dupixent's CSU indication to children as young as two years. The drug is now approved for children under 12 across four chronic diseases driven partly by type 2 inflammation. Clinical studies showed Dupixent significantly reduced urticaria activity, including itch and hives, compared with placebo at Week 24. Safety results were consistent with Dupixent's known profile in dermatological indications. A supplemental biologics licence application is under review in the US for the same patient population.

The Associated Press
Mar 31st, 2026
Sanofi's Rezurock approved in EU for chronic graft-versus-host disease treatment

The European Commission has granted conditional marketing authorisation for Sanofi's Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 years and older weighing at least 40 kg. The treatment is approved for patients when other options provide limited benefit or have been exhausted. The approval follows a positive opinion from the European Medicines Agency and is based on the ROCKstar phase 2 study, which demonstrated a 74% overall response rate. Nearly half of chronic GVHD patients require third-line treatment, yet therapeutic options have remained limited in the EU. Rezurock is already approved in 20 countries, including the US, UK and Canada. More than 20,000 patients have been treated with the medicine since its first US approval in July 2021.

Yahoo Finance
Mar 30th, 2026
Bernstein initiates Sanofi with 'outperform' rating, $123 target price

Bernstein analyst Justin Smith has initiated coverage of Sanofi with an "Outperform" rating and a price target of €110, representing 37% upside from current levels. The analyst believes the French biopharmaceutical company's new chief executive will unlock shareholder value. Sanofi appointed Belén Garijo, former CEO of Germany's Merck KGaA, as its new chief executive in February. The 65-year-old Spanish executive will take charge in late April, replacing Paul Hudson after his six-year tenure. The company says Garijo will strengthen productivity, governance and innovation capacity in research and development. Sanofi shares have declined over 4.5% since the beginning of 2025. The stock trades at a forward price-to-earnings ratio of 9.26.